An interventional study of Methylene Blue in Schizophrenia and Other Psychotic Disorders and Healthy Adult, sponsored by King's College London. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by King's College London · Not applicable, Interventional, and Other
This study tested whether intravenous methylene blue changes brain activity during a working-memory task differently in adults with schizophrenia taking stable antipsychotic medication and healthy volunteers. Each participant received methylene blue and a placebo solution with no methylene blue at separate visits and completed the task during functional magnetic resonance imaging (fMRI)
3,539 studies on the registry are indexed under Schizophrenia; 473 are open to participants now.
This study's enrollment of 53 is below the median of 70 across 2,924 interventional studies indexed under Schizophrenia.
Browse Schizophrenia studies →King's College London is the lead sponsor of 519 studies on the registry; 126 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Placebo first drug second
Drug: Methylene Blue
Drug first placebo second
Drug: Methylene Blue
methylene blue i.v. 0.5mg/kg
FMRI BOLD response
FMRI BOLD response during working memory task
Time frame: Day 1 [on day of drug/placebo administration]
Plan to share: Yes — only IPD used in the results publication
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methylene Blue